- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.04. | Lexeo Enters License Agreement for Friedreich Ataxia Treatment | 1 | Contract Pharma | ||
| 22.04. | Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy | 251 | GlobeNewswire (Europe) | Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN... ► Artikel lesen | |
| 17.04. | Lexeo wins fast track designation for Friedreich's ataxia gene therapy | 2 | Pharmaceutical Technology | ||
| 16.04. | Lexeo's LX2006 Gene Therapy Gets FDA Fast Track Designation; Stock Up In Pre-market | 1 | RTTNews | ||
| 16.04. | Lexeo Therapeutics rises after receiving fast track tag for gene therapy | 1 | Reuters | ||
| 16.04. | Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy | 69 | GlobeNewswire (Europe) | NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular... ► Artikel lesen | |
| 16.04. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.04. | Lexeo Therapeutics files to sell 6.97M shares of common stock for holders | 1 | Seeking Alpha | ||
| 09.04. | Lexeo Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 13.03. | Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing | 1 | GlobeNewswire (USA) | ||
| 11.03. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.03. | Lexeo Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Lexeo Therapeutics announces $95M private equity placement | 1 | Seeking Alpha | ||
| 11.03. | Lexeo Therapeutics GAAP EPS of -$0.86 misses by $0.15 | 1 | Seeking Alpha | ||
| 11.03. | Lexeo Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.03. | Lexeo Therapeutics secures $95 million in private placement | 1 | Investing.com | ||
| 11.03. | Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | 295 | GlobeNewswire (Europe) | Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data... ► Artikel lesen | |
| 11.03. | Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing | 1 | GlobeNewswire (USA) | ||
| 05.02. | Lexeo Therapeutics announces new executive appointments | 1 | Seeking Alpha | ||
| 05.02. | Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments | 375 | GlobeNewswire (Europe) | NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MORPHOSYS | 67,10 | -1,11 % | EQS-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MorphoSys AG
MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
22.04.2024 / 16:00 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 25,300 | +31,43 % | PEGY, CGEM and IFBD among mid-day movers | ||
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| CABALETTA BIO | 11,010 | -9,61 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,530 | +3,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| IMMUNOVANT | 27,170 | -2,09 % | Should You Hold Immunovant (IMVT)? | ||
| AVIDITY BIOSCIENCES | 24,360 | +2,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| KEROS THERAPEUTICS | 57,86 | +6,77 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,730 | +4,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| ARCELLX | 51,92 | +1,05 % | Should You Be Bullish on Arcellx (ACLX)? | ||
| DAY ONE BIOPHARMACEUTICALS | 14,920 | +12,94 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 33,370 | +0,06 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| NUVALENT | 66,86 | +1,20 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,470 | -1,40 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 29,320 | +1,35 % | Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist | PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and... ► Artikel lesen |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,80 % bei einem Aktienkurs von 12,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
